CA2516497A1 - In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes - Google Patents
In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes Download PDFInfo
- Publication number
- CA2516497A1 CA2516497A1 CA002516497A CA2516497A CA2516497A1 CA 2516497 A1 CA2516497 A1 CA 2516497A1 CA 002516497 A CA002516497 A CA 002516497A CA 2516497 A CA2516497 A CA 2516497A CA 2516497 A1 CA2516497 A1 CA 2516497A1
- Authority
- CA
- Canada
- Prior art keywords
- sensor
- analyte
- fluorescence
- fluorescent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 95
- 238000001727 in vivo Methods 0.000 title claims description 36
- 239000012491 analyte Substances 0.000 claims abstract description 152
- 230000005284 excitation Effects 0.000 claims abstract description 110
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 108
- 230000004044 response Effects 0.000 claims abstract description 69
- 238000012544 monitoring process Methods 0.000 claims abstract description 58
- 238000004590 computer program Methods 0.000 claims abstract description 57
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 41
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 30
- 230000000694 effects Effects 0.000 claims abstract description 28
- 230000003287 optical effect Effects 0.000 claims abstract description 27
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 230000003285 pharmacodynamic effect Effects 0.000 claims abstract description 18
- 230000001413 cellular effect Effects 0.000 claims abstract description 16
- 238000001415 gene therapy Methods 0.000 claims abstract description 15
- 238000012986 modification Methods 0.000 claims abstract description 9
- 230000004048 modification Effects 0.000 claims abstract description 9
- 239000000693 micelle Substances 0.000 claims abstract description 7
- 239000003053 toxin Substances 0.000 claims abstract description 7
- 231100000765 toxin Toxicity 0.000 claims abstract description 7
- 238000012790 confirmation Methods 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 54
- 238000005259 measurement Methods 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 21
- 230000014759 maintenance of location Effects 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000011156 evaluation Methods 0.000 claims description 13
- 238000011287 therapeutic dose Methods 0.000 claims description 12
- 230000036962 time dependent Effects 0.000 claims description 12
- 230000002349 favourable effect Effects 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 238000005070 sampling Methods 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000004593 Epoxy Substances 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 230000009120 phenotypic response Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 82
- 239000000523 sample Substances 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 39
- 229940022353 herceptin Drugs 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 20
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 239000000975 dye Substances 0.000 description 16
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 15
- 239000000835 fiber Substances 0.000 description 15
- 101150029707 ERBB2 gene Proteins 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 238000002372 labelling Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000011580 nude mouse model Methods 0.000 description 12
- 210000003462 vein Anatomy 0.000 description 12
- 238000010586 diagram Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000000562 conjugate Substances 0.000 description 10
- 230000015654 memory Effects 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 9
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 9
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000012114 Alexa Fluor 647 Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 239000003068 molecular probe Substances 0.000 description 8
- 229960004641 rituximab Drugs 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000012110 Alexa Fluor 594 Substances 0.000 description 4
- 206010056740 Genital discharge Diseases 0.000 description 4
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 229940116978 human epidermal growth factor Drugs 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940127093 camptothecin Drugs 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 238000011846 endoscopic investigation Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- YBGGBHCJSAEIAS-UHFFFAOYSA-N n-[5-[2-(2,6-dichlorophenyl)-5-(difluoromethyl)pyrazol-3-yl]-1,3-thiazol-2-yl]cyclopropanecarboxamide Chemical compound ClC=1C=CC=C(Cl)C=1N1N=C(C(F)F)C=C1C(S1)=CN=C1NC(=O)C1CC1 YBGGBHCJSAEIAS-UHFFFAOYSA-N 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- 150000003732 xanthenes Chemical class 0.000 description 3
- VRBFTYUMFJWSJY-UHFFFAOYSA-N 28804-46-8 Chemical compound ClC1CC(C=C2)=CC=C2C(Cl)CC2=CC=C1C=C2 VRBFTYUMFJWSJY-UHFFFAOYSA-N 0.000 description 2
- ISTIXAKUPNGALF-UHFFFAOYSA-N 3-(1h-indol-2-yl)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC=4C=CC=CC=4OC3=O)=CC2=C1 ISTIXAKUPNGALF-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 241000759568 Corixa Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000003325 Ilex Nutrition 0.000 description 2
- 241000209035 Ilex Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 240000005578 Rivina humilis Species 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 229940112129 campath Drugs 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical class ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 150000003983 crown ethers Chemical class 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 108010017271 denileukin diftitox Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088013 hycamtin Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011337 individualized treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940100027 ontak Drugs 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- OIHZGFWAMWHYPA-UHFFFAOYSA-N xanthylium Chemical compound C1=CC=CC2=CC3=CC=CC=C3[O+]=C21 OIHZGFWAMWHYPA-UHFFFAOYSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- PPWRGGIIPLXGJL-UHFFFAOYSA-N 1-Pyrenylsulfate Chemical compound C1=C2C(OS(=O)(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 PPWRGGIIPLXGJL-UHFFFAOYSA-N 0.000 description 1
- IPVYMXZYXFFDGW-UHFFFAOYSA-N 1-methylpiperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)CC1 IPVYMXZYXFFDGW-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
- MUBAIQNAOOUIDW-UHFFFAOYSA-M 3-ethyl-2-[3-(3-ethyl-1,3-benzothiazol-3-ium-2-yl)-2-methylprop-2-enylidene]-1,3-benzothiazole;bromide Chemical compound [Br-].S1C2=CC=CC=C2[N+](CC)=C1/C=C(\C)/C=C1/N(CC)C2=CC=CC=C2S1 MUBAIQNAOOUIDW-UHFFFAOYSA-M 0.000 description 1
- AVEQMYZAGPYSNN-UHFFFAOYSA-N 6,8-difluoro-7-hydroxychromen-2-one Chemical class C1=CC(=O)OC2=C(F)C(O)=C(F)C=C21 AVEQMYZAGPYSNN-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- RRHXPUCIXLAHIY-UHFFFAOYSA-N 7-aminochromen-2-one Chemical class C1=CC(=O)OC2=CC(N)=CC=C21 RRHXPUCIXLAHIY-UHFFFAOYSA-N 0.000 description 1
- 241000030634 Anthene Species 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical class OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000035984 Colonic Polyps Diseases 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- 101100460844 Mus musculus Nr2f6 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000589614 Pseudomonas stutzeri Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000021096 adenomatous colon polyp Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- -1 antibody Proteins 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- BHKICZDKIIDMNR-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound N.N.[Pt+4].[O-]C(=O)C1(C([O-])=O)CCC1 BHKICZDKIIDMNR-UHFFFAOYSA-L 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 101150087654 chrnd gene Proteins 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000012445 drug development testing Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940000733 emcyt Drugs 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- GTSMOYLSFUBTMV-UHFFFAOYSA-N ethidium homodimer Chemical compound [H+].[H+].[Cl-].[Cl-].[Cl-].[Cl-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2C(C)=[N+]1CCCNCCNCCC[N+](C1=CC(N)=CC=C1C1=CC=C(N)C=C11)=C1C1=CC=CC=C1 GTSMOYLSFUBTMV-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229940090411 ifex Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940100029 lysodren Drugs 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940099637 nilandron Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000001055 reflectance spectroscopy Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001154 skull base Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical class OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/417—Evaluating particular organs or parts of the immune or lymphatic systems the bone marrow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44834903P | 2003-02-19 | 2003-02-19 | |
| US60/448,349 | 2003-02-19 | ||
| US47170603P | 2003-05-19 | 2003-05-19 | |
| US60/471,706 | 2003-05-19 | ||
| PCT/US2004/005785 WO2004075032A2 (en) | 2003-02-19 | 2004-02-17 | In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2516497A1 true CA2516497A1 (en) | 2004-09-02 |
Family
ID=32912293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002516497A Abandoned CA2516497A1 (en) | 2003-02-19 | 2004-02-17 | In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7510699B2 (https=) |
| EP (1) | EP1594551A2 (https=) |
| JP (1) | JP4607859B2 (https=) |
| AU (1) | AU2004214420A1 (https=) |
| CA (1) | CA2516497A1 (https=) |
| WO (1) | WO2004075032A2 (https=) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263375B2 (en) | 2002-12-20 | 2012-09-11 | Acea Biosciences | Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology |
| US10215748B2 (en) | 2002-12-20 | 2019-02-26 | Acea Biosciences, Inc. | Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways |
| US10539523B2 (en) | 2002-12-20 | 2020-01-21 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties |
| US11346797B2 (en) | 2002-12-20 | 2022-05-31 | Agilent Technologies, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties |
| US10551371B2 (en) | 2003-11-10 | 2020-02-04 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function |
| EP1692258A4 (en) | 2003-11-12 | 2007-03-21 | Xiao Xu | REAL-TIME ELECTRONIC CELL DETECTION SYSTEMS FOR CELL-BASED TESTS |
| US9011329B2 (en) * | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
| US9801527B2 (en) * | 2004-04-19 | 2017-10-31 | Gearbox, Llc | Lumen-traveling biological interface device |
| US8019413B2 (en) | 2007-03-19 | 2011-09-13 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
| US8353896B2 (en) * | 2004-04-19 | 2013-01-15 | The Invention Science Fund I, Llc | Controllable release nasal system |
| US7375347B2 (en) * | 2004-04-26 | 2008-05-20 | Sensors For Medicine And Science, Inc. | Systems and methods for extending the useful life of optical sensors |
| JP4619803B2 (ja) * | 2005-01-26 | 2011-01-26 | 富士フイルム株式会社 | 蛍光断層画像取得装置 |
| US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
| CA2789262C (en) | 2005-04-28 | 2016-10-04 | Proteus Digital Health, Inc. | Pharma-informatics system |
| US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
| US8900133B2 (en) * | 2005-05-13 | 2014-12-02 | The University Of North Carolina At Chapel Hill | Capsule imaging devices, systems and methods for in vivo imaging applications |
| US7485875B2 (en) * | 2005-07-22 | 2009-02-03 | Carl Zeiss Microimaging Gmbh | Resolution-enhanced luminescence microscopy |
| MX2008002201A (es) * | 2005-08-16 | 2008-10-21 | Skin Cancer Scanning Ltd | Tecnologias infrarrojas pasivas y visuales-opticas combinadas y el sistema correspondiente para la deteccion e identificacion de precursores de cancer de piel, lunares y tumores para el diagnostico temprano. |
| DE102005041054A1 (de) * | 2005-08-30 | 2007-03-01 | Giesecke & Devrient Gmbh | Verfahren und Vorrichtung zur Echtheitsprüfung von Banknoten |
| JP2009517115A (ja) * | 2005-11-25 | 2009-04-30 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 光学蛍光トモグラフィ |
| US8095198B2 (en) * | 2006-01-31 | 2012-01-10 | Warsaw Orthopedic. Inc. | Methods for detecting osteolytic conditions in the body |
| US7918796B2 (en) * | 2006-04-11 | 2011-04-05 | Warsaw Orthopedic, Inc. | Volumetric measurement and visual feedback of tissues |
| US9408530B2 (en) | 2006-04-12 | 2016-08-09 | Gearbox, Llc | Parameter-based navigation by a lumen traveling device |
| US20080058788A1 (en) * | 2006-04-12 | 2008-03-06 | Searete Llc., A Limited Liability Corporation Of The State Of Delaware | Autofluorescent imaging and target ablation |
| US20080058786A1 (en) * | 2006-04-12 | 2008-03-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Autofluorescent imaging and target ablation |
| HRP20060149B1 (en) * | 2006-04-19 | 2008-11-30 | Institut "Ruđer Bošković" | Intelligent sequential illuminator photodynamic therapy |
| DE102006050886B4 (de) * | 2006-10-27 | 2016-12-22 | Siemens Healthcare Gmbh | Medizinisches Instrument und Einrichtung zur Erzeugung von Gewebeschnittbildern |
| WO2008066054A1 (en) * | 2006-11-28 | 2008-06-05 | Nippon Sheet Glass Company, Limited | Detection system and its probe |
| WO2008105435A1 (ja) | 2007-02-28 | 2008-09-04 | Nippon Sheet Glass Company, Limited | 蛍光検出システム |
| EP2063771A1 (en) | 2007-03-09 | 2009-06-03 | Proteus Biomedical, Inc. | In-body device having a deployable antenna |
| CA2686089A1 (en) * | 2007-05-16 | 2008-11-20 | Ge Healthcare As | Optical imaging agents |
| ATE551073T1 (de) * | 2007-05-16 | 2012-04-15 | Ge Healthcare As | Markierte hgf-bindende peptide für bildgebung |
| GB0712109D0 (en) * | 2007-06-22 | 2007-08-01 | Edinburgh Instr | Fluorescence lifetime and fluorescence assays |
| CA2692159C (en) * | 2007-06-22 | 2016-09-13 | Barry S. Cooperman | Fluorescent labeling of transfer rna and study of protein synthesis |
| US20090018403A1 (en) | 2007-07-12 | 2009-01-15 | Sicel Technologies, Inc. | Trackable implantable sensor devices, systems, and related methods of operation |
| US9186089B2 (en) | 2007-09-14 | 2015-11-17 | Medtronic Monitoring, Inc. | Injectable physiological monitoring system |
| WO2009036306A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Adherent cardiac monitor with advanced sensing capabilities |
| WO2009036333A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Dynamic pairing of patients to data collection gateways |
| EP2194847A1 (en) | 2007-09-14 | 2010-06-16 | Corventis, Inc. | Adherent device with multiple physiological sensors |
| WO2009036348A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Medical device automatic start-up upon contact to patient tissue |
| EP2200499B1 (en) | 2007-09-14 | 2019-05-01 | Medtronic Monitoring, Inc. | Multi-sensor patient monitor to detect impending cardiac decompensation |
| US8275432B2 (en) * | 2007-12-12 | 2012-09-25 | Medtronic, Inc. | Implantable optical sensor and method for manufacture |
| EP3300652A1 (en) * | 2008-02-12 | 2018-04-04 | Innurvation, Inc. | Radial scanner imaging system |
| US8529441B2 (en) * | 2008-02-12 | 2013-09-10 | Innurvation, Inc. | Ingestible endoscopic optical scanning device |
| JP5405500B2 (ja) | 2008-03-12 | 2014-02-05 | コーヴェンティス，インク． | 心調律に基づく心代償不全予測 |
| US8412317B2 (en) | 2008-04-18 | 2013-04-02 | Corventis, Inc. | Method and apparatus to measure bioelectric impedance of patient tissue |
| WO2009137440A1 (en) | 2008-05-05 | 2009-11-12 | Acea Biosciences, Inc. | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
| CA3162577C (en) | 2008-05-20 | 2023-09-26 | University Health Network | Device and method for fluorescence-based imaging and monitoring |
| CN102176862B (zh) | 2008-08-13 | 2014-10-22 | 普罗透斯数字保健公司 | 可摄入电路 |
| DK2317911T3 (en) * | 2008-08-22 | 2019-01-28 | Medibeacon Inc | TRANSCUTAN ORGAN FUNCTION MEASUREMENT |
| GB2480965B (en) * | 2009-03-25 | 2014-10-08 | Proteus Digital Health Inc | Probablistic pharmacokinetic and pharmacodynamic modeling |
| WO2010129288A2 (en) | 2009-04-28 | 2010-11-11 | Proteus Biomedical, Inc. | Highly reliable ingestible event markers and methods for using the same |
| AU2010244431B2 (en) * | 2009-05-05 | 2015-05-14 | Lumito Ab | A system, method, and luminescent marker for improved diffuse luminescent imaging or tomography in scattering media |
| US20110071403A1 (en) * | 2009-09-21 | 2011-03-24 | Board Of Regents Of The University Of Texas System | Functional near-infrared fluorescence lymphatic mapping for diagnosing, accessing, monitoring and directing therapy of lymphatic disorders |
| EP2720060A1 (en) * | 2009-09-28 | 2014-04-16 | Koninklijke Philips N.V. | A biosensor system for single particle detection |
| JP2011131002A (ja) * | 2009-12-25 | 2011-07-07 | Fujifilm Corp | 蛍光画像撮像装置 |
| WO2011082314A2 (en) * | 2009-12-30 | 2011-07-07 | Brockman Holdings Llc | System, device, and method for determination of intraocular pressure |
| WO2011093914A1 (en) * | 2010-01-29 | 2011-08-04 | Medtronic, Inc. | Optical sensor for medical device |
| CN102905672B (zh) | 2010-04-07 | 2016-08-17 | 普罗秋斯数字健康公司 | 微型可吞服装置 |
| US9000401B2 (en) | 2010-07-07 | 2015-04-07 | Institut National D'optique | Fiber optic radiochromic dosimeter probe and method to make the same |
| EP2642983A4 (en) | 2010-11-22 | 2014-03-12 | Proteus Digital Health Inc | DEVICE INGREABLE WITH PHARMACEUTICAL PRODUCT |
| WO2012081336A1 (ja) * | 2010-12-13 | 2012-06-21 | オリンパスメディカルシステムズ株式会社 | 医療装置 |
| EP2683413A1 (en) * | 2011-03-07 | 2014-01-15 | F.Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
| WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| WO2013112709A1 (en) * | 2012-01-24 | 2013-08-01 | Niedre Mark | Systems and methods for sensing, enumerating and imaging rare cells with diffuse light |
| WO2013177539A1 (en) | 2012-05-24 | 2013-11-28 | University Of Utah Research Foundation | Compounds, sensors, methods, and systems for detecting gamma radiation |
| CN104487347B (zh) | 2012-07-23 | 2017-09-01 | 普罗秋斯数字健康公司 | 用于制造包括电子器件的片剂的方法和系统 |
| CA2888871C (en) | 2012-10-18 | 2016-08-09 | Proteus Digital Health, Inc. | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
| JP5712337B2 (ja) * | 2012-12-27 | 2015-05-07 | パナソニック株式会社 | 被検物質を検出する方法、および、検出システム |
| WO2014120669A1 (en) | 2013-01-29 | 2014-08-07 | Proteus Digital Health, Inc. | Highly-swellable polymeric films and compositions comprising the same |
| US10175376B2 (en) | 2013-03-15 | 2019-01-08 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
| US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
| US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
| DE102013226777B4 (de) * | 2013-12-19 | 2023-01-12 | Sirona Dental Systems Gmbh | Beobachtungseinheit zur Erkennung von Fluoreszenz und eine Vorrichtung zur Erkennung von Karies |
| WO2016011534A1 (en) | 2014-07-24 | 2016-01-28 | University Health Network | Collection and analysis of data for diagnostic purposes |
| WO2016149701A1 (en) * | 2015-03-19 | 2016-09-22 | The Regents Of The University Of Michigan | System for analyzing tissue |
| JP6467275B2 (ja) * | 2015-04-13 | 2019-02-06 | 富士フイルム株式会社 | 内視鏡用光源装置及び内視鏡システム |
| CN104970806B (zh) * | 2015-07-12 | 2017-08-04 | 北京泱深生物信息技术有限公司 | 一种用于癌症复发实时动态监测的智能设备 |
| US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
| US10579891B2 (en) * | 2015-08-10 | 2020-03-03 | AI Biomed Corp | Optical overlay device |
| HK1258798A1 (zh) * | 2015-11-20 | 2019-11-22 | 安捷伦科技有限公司 | 癌细胞的细胞基质阻抗监测 |
| US12066428B2 (en) | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
| CN109843149B (zh) | 2016-07-22 | 2020-07-07 | 普罗秋斯数字健康公司 | 可摄入事件标记的电磁感测和检测 |
| US10820831B2 (en) | 2016-10-26 | 2020-11-03 | Proteus Digital Health, Inc. | Methods for manufacturing capsules with ingestible event markers |
| CA3051963A1 (en) | 2017-01-30 | 2018-08-02 | Medibeacon Inc. | Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflection corrections |
| EP3589299B1 (en) | 2017-03-03 | 2025-04-09 | Agilent Technologies, Inc. | METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES |
| US11013436B2 (en) | 2017-09-06 | 2021-05-25 | Medtronic, Inc. | Marker monitoring via a medical device |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| WO2020104628A1 (en) * | 2018-11-21 | 2020-05-28 | Bioncotech Therapeutics S.L | Nanoplexed poly(i:c) formulations and uses thereof |
| WO2020124266A1 (en) * | 2018-12-21 | 2020-06-25 | The Royal Institution For The Advancement Of Learning/Mcgill University | Radiation dosimeter |
| WO2020176906A1 (en) | 2019-02-26 | 2020-09-03 | Ai Biomed Corp. | Tissue detection system and methods for use thereof |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| US11759166B2 (en) | 2019-09-20 | 2023-09-19 | Bard Access Systems, Inc. | Automatic vessel detection tools and methods |
| USD941488S1 (en) | 2020-02-07 | 2022-01-18 | Agilent Technologies, Inc. | Instrument for analyzing biological cells |
| US20210301245A1 (en) | 2020-03-29 | 2021-09-30 | Agilent Technologies, Inc. | Systems and methods for electronically and optically monitoring biological samples |
| CN216135922U (zh) | 2020-09-08 | 2022-03-29 | 巴德阿克塞斯系统股份有限公司 | 动态调整超声成像系统 |
| CN114159098B (zh) | 2020-09-10 | 2026-01-02 | 巴德阿克塞斯系统股份有限公司 | 具有压力测量能力的超声探测器 |
| CN116249504B (zh) * | 2020-09-29 | 2025-11-28 | 奥林巴斯株式会社 | 辅助装置、内窥镜系统、辅助方法以及存储介质 |
| US12185441B2 (en) * | 2020-09-30 | 2024-12-31 | Jdrf Electromag Engineering Inc. | Autonomous light power density detectors |
| EP4247267A1 (en) * | 2020-11-24 | 2023-09-27 | Bard Access Systems, Inc. | Ultrasound system with target and medical instrument awareness |
| WO2022119856A1 (en) | 2020-12-01 | 2022-06-09 | Bard Access Systems, Inc. | Ultrasound system with pressure and flow determination capability |
| CN114569155A (zh) | 2020-12-01 | 2022-06-03 | 巴德阿克塞斯系统股份有限公司 | 超声成像系统和用于通过其获得超声图像的方法 |
| CN217960146U (zh) | 2021-04-15 | 2022-12-06 | 巴德阿克塞斯系统股份有限公司 | 超声成像系统 |
| EP4362027A4 (en) * | 2021-06-25 | 2025-11-12 | Portrai Inc | EXPLORATION APPARATUS, SYSTEM AND COMPUTER PROGRAM FOR EXPLORING MOLECULAR MARKER OR PHYSIOLOGICAL ACTIVITY INFORMATION IN TISSUE RELATING TO A DISTRIBUTION OR PHYSIOLOGICAL ACTIVITY OF MATERIAL UNDER EXPLORATION |
| CN113633261A (zh) * | 2021-08-11 | 2021-11-12 | 南京航空航天大学 | 一种基于荧光监测的多通道在体药代分析系统 |
| US12279758B2 (en) | 2021-09-27 | 2025-04-22 | Ai Biomed Corp. | Tissue detection systems and methods |
| US11974726B2 (en) | 2021-09-27 | 2024-05-07 | Ai Biomed Corp. | Tissue detection systems and methods |
| US12376817B2 (en) | 2021-11-03 | 2025-08-05 | Bard Access Systems, Inc. | Optimized functionality through interoperation of doppler and image based vessel differentiation |
| US12514533B2 (en) | 2022-03-01 | 2026-01-06 | Bard Access Systems, Inc. | Ultrasound imaging system |
| US12514532B2 (en) | 2022-03-01 | 2026-01-06 | Bard Access Systems, Inc. | Ultrasound imaging system |
| EP4489661B1 (en) | 2022-03-16 | 2025-10-29 | Bard Access Systems, Inc. | Ultrasound imaging system |
| EP4568563A1 (en) * | 2022-08-10 | 2025-06-18 | University of Cincinnati | Biosensor system for drug efficacy monitoring |
| USD1052412S1 (en) | 2023-01-06 | 2024-11-26 | Medibeacon Inc. | Sensor |
| USD1051738S1 (en) | 2023-01-06 | 2024-11-19 | Medibeacon Inc. | Sensor ring |
| WO2025019535A1 (en) * | 2023-07-20 | 2025-01-23 | The Johns Hopkins University | Methods and related aspects of biosensors |
Family Cites Families (185)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US424453A (en) * | 1890-04-01 | William f | ||
| US32361A (en) * | 1861-05-21 | Portable filter | ||
| DE332075C (de) | 1919-08-19 | 1921-01-21 | Walther Lenke | Ellipsenzirkel |
| JPS36022343B1 (https=) | 1959-12-24 | 1961-11-18 | Univ Tokyo | |
| US3638640A (en) * | 1967-11-01 | 1972-02-01 | Robert F Shaw | Oximeter and method for in vivo determination of oxygen saturation in blood using three or more different wavelengths |
| US3980075A (en) * | 1973-02-08 | 1976-09-14 | Audronics, Inc. | Photoelectric physiological measuring apparatus |
| US3972320A (en) * | 1974-08-12 | 1976-08-03 | Gabor Ujhelyi Kalman | Patient monitoring system |
| US4163380A (en) * | 1977-10-11 | 1979-08-07 | Lockheed Corporation | Forming of preconsolidated metal matrix composites |
| USRE32361E (en) | 1979-05-14 | 1987-02-24 | Medtronic, Inc. | Implantable telemetry transmission system for analog and digital data |
| US4326535A (en) * | 1980-05-13 | 1982-04-27 | Akron City Hospital | Circuit and method for the radiotelemetry of esophageal pH in an ECG radiotelemetry system |
| US4361153A (en) | 1980-05-27 | 1982-11-30 | Cordis Corporation | Implant telemetry system |
| US4494545A (en) * | 1980-05-27 | 1985-01-22 | Cordis Corporation | Implant telemetry system |
| US4556063A (en) | 1980-10-07 | 1985-12-03 | Medtronic, Inc. | Telemetry system for a medical device |
| US4523279A (en) * | 1980-11-24 | 1985-06-11 | Oximetrix, Inc. | Apparatus for determining oxygen saturation levels in blood |
| US4397313A (en) * | 1981-08-03 | 1983-08-09 | Clini-Therm Corporation | Multiple microwave applicator system and method for microwave hyperthermia treatment |
| US4397314A (en) | 1981-08-03 | 1983-08-09 | Clini-Therm Corporation | Method and apparatus for controlling and optimizing the heating pattern for a hyperthermia system |
| US4416283A (en) | 1981-08-31 | 1983-11-22 | Cordis Corporation | Programming and telemetry system for biomedical implantable device |
| CA1188431A (en) | 1981-10-02 | 1985-06-04 | Canadian Astronautics Limited | Direct reading dosimeter |
| US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
| DE3150052C2 (de) * | 1981-12-17 | 1985-02-21 | Sterimed Gesellschaft für medizinischen Bedarf mbH, 6600 Saarbrücken | Katheter zur Katheterung zentraler Venen |
| US5186172A (en) * | 1982-03-22 | 1993-02-16 | Mountpelier Investments, S.A. | Remote sensing tonometric catheter apparatus |
| DE3219558C2 (de) | 1982-05-25 | 1986-10-23 | Norbert H.L. Dr.-Ing. 5173 Aldenhoven Koster | Vorrichtung zur Bestimmung der lokalen Temperatur in lebendem Gewebe |
| US4571292A (en) * | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
| CH658729A5 (de) | 1982-09-17 | 1986-11-28 | Lehner Max & Co Ag | Vorrichtung zur registrierung der strahlenbelastung von mit strahlung umgehenden personen. |
| US4571589A (en) * | 1982-11-22 | 1986-02-18 | Cordis Corporation | Biomedical implant with high speed, low power two-way telemetry |
| US4961422A (en) | 1983-01-21 | 1990-10-09 | Marchosky J Alexander | Method and apparatus for volumetric interstitial conductive hyperthermia |
| GB2142831B (en) * | 1983-01-21 | 1987-02-11 | Jose Alexander Marchosky | Implantable hyperthermia device and system |
| US4575676A (en) * | 1983-04-04 | 1986-03-11 | Advanced Research And Applications Corporation | Method and apparatus for radiation testing of electron devices |
| GB2140563B (en) | 1983-04-27 | 1987-03-04 | Critikon Inc | Method and apparatus for zero calibration of oxygen-sensing polarographic devices |
| US4543953A (en) | 1983-07-18 | 1985-10-01 | Cordis Corporation | Analog telemetry system for biomedical implant |
| US4655880A (en) * | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
| US4519401A (en) * | 1983-09-20 | 1985-05-28 | Case Western Reserve University | Pressure telemetry implant |
| FI68734C (fi) | 1983-11-11 | 1985-10-10 | Seppo Saeynaejaekangas | Foerfarande och anordning foer telemetrisk maetning av hjaertslag och ekg-signal med anvaendande av ett magnetiskt naerfaelt |
| GB8422876D0 (en) | 1984-09-11 | 1984-10-17 | Secr Defence | Silicon implant devices |
| US4638436A (en) * | 1984-09-24 | 1987-01-20 | Labthermics Technologies, Inc. | Temperature control and analysis system for hyperthermia treatment |
| US4681111A (en) * | 1985-04-05 | 1987-07-21 | Siemens-Pacesetter, Inc. | Analog and digital telemetry system for an implantable device |
| US4651741A (en) * | 1985-05-30 | 1987-03-24 | Baxter Travenol Laboratories, Inc. | Method and apparatus for determining oxygen saturation in vivo |
| US5012411A (en) * | 1985-07-23 | 1991-04-30 | Charles J. Policastro | Apparatus for monitoring, storing and transmitting detected physiological information |
| CA1204885A (en) * | 1985-09-18 | 1986-05-20 | Thomson & Nielson Electronics Ltd. | Dosimeter |
| US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
| FI872885A7 (fi) * | 1986-07-01 | 1988-01-02 | Terumo Corp | Anordning foer maetning av biologisk information. |
| US4976266A (en) | 1986-08-29 | 1990-12-11 | United States Department Of Energy | Methods of in vivo radiation measurement |
| DE3700119A1 (de) * | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | Implantierbarer elektrochemischer sensor |
| US4769547A (en) | 1987-01-27 | 1988-09-06 | Medrad, Inc. | Personal dosimeter having a volume of gas atop an integrated circuit |
| US4970391A (en) | 1987-01-27 | 1990-11-13 | Medrad, Inc. | Radiation detector with an ionizable gas atop an integrated circuit |
| US4804847A (en) * | 1987-01-27 | 1989-02-14 | Medrad, Inc. | Radiation detector with an ionizable gas atop an integrated circuit |
| US4935345A (en) * | 1987-04-07 | 1990-06-19 | Arizona Board Of Regents | Implantable microelectronic biochemical sensor incorporating thin film thermopile |
| US4750495A (en) * | 1987-06-05 | 1988-06-14 | Medtronic, Inc. | Oxygen sensing pacemaker |
| US4796641A (en) * | 1987-07-06 | 1989-01-10 | Data Sciences, Inc. | Device and method for chronic in-vivo measurement of internal body pressure |
| US4847617A (en) * | 1987-08-14 | 1989-07-11 | Siemens-Pacesetter, Inc. | High speed digital telemetry system for implantable devices |
| GB8726933D0 (en) | 1987-11-18 | 1987-12-23 | Cadell T E | Telemetry system |
| US4989601A (en) * | 1988-05-02 | 1991-02-05 | Medical Engineering & Development Institute, Inc. | Method, apparatus, and substance for treating tissue having neoplastic cells |
| US4846191A (en) * | 1988-05-27 | 1989-07-11 | Data Sciences, Inc. | Device for chronic measurement of internal body pressure |
| US4900422A (en) * | 1988-07-05 | 1990-02-13 | Bryan Avron I | System for monitoring and reporting the operability and calibration status of a dissolved oxygen sensor |
| AU634979B2 (en) | 1988-08-26 | 1993-03-11 | Instrumentarium Corporation | Remote sensing tonometric catheter apparatus and method |
| US5098547A (en) * | 1988-10-11 | 1992-03-24 | Bryan Avron I | Dissolved oxygen sensor calibration, monitoring and reporting system |
| US5354314A (en) | 1988-12-23 | 1994-10-11 | Medical Instrumentation And Diagnostics Corporation | Three-dimensional beam localization apparatus and microscope for stereotactic diagnoses or surgery mounted on robotic type arm |
| JP2823688B2 (ja) * | 1989-02-14 | 1998-11-11 | ペースセッター アクチボラゲット | 生体内に植え込み可能な電気医学装置 |
| US5264843A (en) | 1989-04-05 | 1993-11-23 | Siemens Pacesetter, Inc. | High speed reflected impedance telemetry system for implantable medical device |
| US5166073A (en) | 1989-05-05 | 1992-11-24 | The Dow Chemical Company | Miniaturized sensor for ionizing radiation |
| US4944299A (en) * | 1989-08-08 | 1990-07-31 | Siemens-Pacesetter, Inc. | High speed digital telemetry system for implantable device |
| DE3932428A1 (de) | 1989-09-28 | 1991-04-11 | Argumens Gmbh | Vorrichtung zur drahtlosen messung einer lokalen physikalischen groesse |
| US5127404A (en) * | 1990-01-22 | 1992-07-07 | Medtronic, Inc. | Telemetry format for implanted medical device |
| US5354319A (en) | 1990-01-22 | 1994-10-11 | Medtronic, Inc. | Telemetry system for an implantable medical device |
| US5109850A (en) * | 1990-02-09 | 1992-05-05 | Massachusetts Institute Of Technology | Automatic blood monitoring for medication delivery method and apparatus |
| US5008546A (en) * | 1990-06-18 | 1991-04-16 | The Regents Of The University Of California | Intraoperative beta probe and method of using the same |
| US5117113A (en) * | 1990-07-06 | 1992-05-26 | Thompson And Nielson Electronics Ltd. | Direct reading dosimeter |
| US5137022A (en) | 1990-07-13 | 1992-08-11 | Cook Pacemaker Corporation | Synchronous telemetry system and method for an implantable medical device |
| US5252962A (en) * | 1990-08-03 | 1993-10-12 | Bio Medic Data Systems | System monitoring programmable implantable transponder |
| US5163380A (en) | 1990-08-09 | 1992-11-17 | United States Of America | Method and apparatus for assessing metabolic behavioral and physiological status of animals |
| KR930002824B1 (ko) * | 1990-08-21 | 1993-04-10 | 손병기 | 감이온 전계효과 트랜지스터를 이용한 바이오 센서용 측정회로 |
| US5117824A (en) * | 1990-11-14 | 1992-06-02 | Medtronic, Inc. | Apparatus for monitoring electrical physiologic signals |
| JP2646848B2 (ja) * | 1990-11-30 | 1997-08-27 | 日本電気株式会社 | グルコースセンサの測定方法 |
| US5205294A (en) * | 1991-02-19 | 1993-04-27 | Pacific Communications, Inc. | Apparatus and methodology for digital telemetry of biomedical signals |
| US5318023A (en) * | 1991-04-03 | 1994-06-07 | Cedars-Sinai Medical Center | Apparatus and method of use for a photosensitizer enhanced fluorescence based biopsy needle |
| US5377676A (en) * | 1991-04-03 | 1995-01-03 | Cedars-Sinai Medical Center | Method for determining the biodistribution of substances using fluorescence spectroscopy |
| US5159262A (en) | 1991-07-09 | 1992-10-27 | Cascade Microtech, Inc. | Method for measuring the electrical and optical performance of on-wafer microwave devices |
| US5264103A (en) | 1991-10-18 | 1993-11-23 | Matsushita Electric Industrial Co., Ltd. | Biosensor and a method for measuring a concentration of a substrate in a sample |
| DE4139122C1 (https=) * | 1991-11-28 | 1993-04-08 | Fenzlein, Paul-Gerhard, 8500 Nuernberg, De | |
| GB9200569D0 (en) | 1992-01-11 | 1992-03-11 | Atomic Energy Authority Uk | Semiconductor dosimeter |
| NL9200207A (nl) | 1992-02-05 | 1993-09-01 | Nedap Nv | Implanteerbare biomedische sensorinrichting, in het bijzonder voor meting van de glucoseconcentratie. |
| US5444254A (en) | 1992-06-12 | 1995-08-22 | Thomson And Nielsen Electronics Ltd. | Flexible radiation probe |
| US5355880A (en) * | 1992-07-06 | 1994-10-18 | Sandia Corporation | Reliable noninvasive measurement of blood gases |
| US5676651A (en) * | 1992-08-06 | 1997-10-14 | Electric Boat Corporation | Surgically implantable pump arrangement and method for pumping body fluids |
| US5330634A (en) * | 1992-08-28 | 1994-07-19 | Via Medical Corporation | Calibration solutions useful for analyses of biological fluids and methods employing same |
| EP0670693B1 (en) | 1992-11-09 | 2002-03-06 | iLIFE SYSTEMS, INC. | Apparatus and method for remote monitoring of physiological parameters |
| US5620479A (en) * | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
| US5383909A (en) * | 1993-01-29 | 1995-01-24 | Medtronic, Inc. | Diagnostic telemetry system for an apparatus for detection and treatment of tachycardia and fibrillation |
| US5341805A (en) * | 1993-04-06 | 1994-08-30 | Cedars-Sinai Medical Center | Glucose fluorescence monitor and method |
| US5383912A (en) * | 1993-05-05 | 1995-01-24 | Intermedics, Inc. | Apparatus for high speed data communication between an external medical device and an implantable medical device |
| US5431171A (en) | 1993-06-25 | 1995-07-11 | The Regents Of The University Of California | Monitoring fetal characteristics by radiotelemetric transmission |
| US5324315A (en) * | 1993-08-12 | 1994-06-28 | Medtronic, Inc. | Closed-loop downlink telemetry and method for implantable medical device |
| US5497772A (en) * | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
| US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
| US5431717A (en) * | 1993-12-03 | 1995-07-11 | Geobiotics, Inc. | Method for rendering refractory sulfide ores more susceptible to biooxidation |
| DE4341903A1 (de) | 1993-12-09 | 1995-06-14 | Josef Prof Dr Rer Nat Binder | Implantierbares telemetrisches Endosystem |
| US5476488A (en) | 1993-12-15 | 1995-12-19 | Pacesetter, Inc. | Telemetry system power control for implantable medical devices |
| DE4444577B4 (de) | 1993-12-15 | 2005-02-10 | Bridgestone Corp. | Verfahren zur Herstellung eines Lichtwellenleiters |
| IES66403B2 (en) | 1993-12-31 | 1995-12-27 | Rodney Arthur Stafford | Electronic animal identification device |
| SE9400622D0 (sv) | 1994-02-23 | 1994-02-23 | Siemens Elema Ab | Medicinskt implantat |
| NL9400534A (nl) * | 1994-04-05 | 1995-11-01 | Rijksuniversiteit | Systeem voor het bepalen van een samenstelling van radionucliden. |
| US5507786A (en) * | 1994-04-14 | 1996-04-16 | Pacesetter, Inc. | System and method for measuring and storing parametric data pertaining to operating characteristics of an implantable medical device |
| US5549654A (en) | 1994-04-15 | 1996-08-27 | Medtronic, Inc. | Interactive interpretation of event markers in body-implantable medical device |
| SE9401402D0 (sv) * | 1994-04-25 | 1994-04-25 | Siemens Elema Ab | Medicinskt implantat |
| US5470345A (en) | 1994-06-16 | 1995-11-28 | Medtronic, Inc. | Implantable medical device with multi-layered ceramic enclosure |
| US6093381A (en) * | 1994-07-13 | 2000-07-25 | Neoprobe Corporation | Modulation of the sensitivity of tumor cells to chemotherapeutics |
| US5466246A (en) | 1994-07-29 | 1995-11-14 | Pacesetter, Inc. | Telemetry receiver for implantable device, incorporating digital signal processing |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5571148A (en) | 1994-08-10 | 1996-11-05 | Loeb; Gerald E. | Implantable multichannel stimulator |
| US5572996A (en) | 1994-09-19 | 1996-11-12 | Pdt Systems, Inc. | In vivo pharmacokinetics of photosensitive drugs and method |
| US5626630A (en) * | 1994-10-13 | 1997-05-06 | Ael Industries, Inc. | Medical telemetry system using an implanted passive transponder |
| US5591217A (en) * | 1995-01-04 | 1997-01-07 | Plexus, Inc. | Implantable stimulator with replenishable, high value capacitive power source and method therefor |
| US5606163A (en) * | 1995-01-11 | 1997-02-25 | The United States Of America As Represented By The Secretary Of The Navy | All-optical, rapid readout, fiber-coupled thermoluminescent dosimeter system |
| US5620472A (en) * | 1995-01-12 | 1997-04-15 | Pacesetter, Inc. | Apparatus and method for dynamically interpreting and displaying a real-time telemetry link |
| US5562713A (en) | 1995-01-18 | 1996-10-08 | Pacesetter, Inc. | Bidirectional telemetry apparatus and method for implantable device |
| US5593430A (en) * | 1995-01-27 | 1997-01-14 | Pacesetter, Inc. | Bus system for interconnecting an implantable medical device with a plurality of sensors |
| DE69600098T2 (de) * | 1995-02-04 | 1998-06-10 | Baumann & Haldi S.A., Fleurier | Einzelne Anordnung zur Messung, Verarbeitung und Übertragung von im wesentlichen physiologischen Parametern |
| US5596199A (en) * | 1995-02-06 | 1997-01-21 | Clemson University | Passive solid state microdosimeter with electronic readout |
| US5517313A (en) * | 1995-02-21 | 1996-05-14 | Colvin, Jr.; Arthur E. | Fluorescent optical sensor |
| US5556421A (en) | 1995-02-22 | 1996-09-17 | Intermedics, Inc. | Implantable medical device with enclosed physiological parameter sensors or telemetry link |
| US5564434A (en) | 1995-02-27 | 1996-10-15 | Medtronic, Inc. | Implantable capacitive absolute pressure and temperature sensor |
| US5535752A (en) * | 1995-02-27 | 1996-07-16 | Medtronic, Inc. | Implantable capacitive absolute pressure and temperature monitor system |
| US5633161A (en) * | 1995-03-29 | 1997-05-27 | Millennium Pharmaceuticals, Inc. | Murine gene fomy030 coding for tumor progression inhibitor |
| US5840148A (en) | 1995-06-30 | 1998-11-24 | Bio Medic Data Systems, Inc. | Method of assembly of implantable transponder |
| US5759199A (en) * | 1995-08-02 | 1998-06-02 | Pacesetter, Inc. | System and method for ambulatory monitoring and programming of an implantable medical device |
| US5720771A (en) * | 1995-08-02 | 1998-02-24 | Pacesetter, Inc. | Method and apparatus for monitoring physiological data from an implantable medical device |
| US5732704A (en) * | 1995-10-13 | 1998-03-31 | Neoprobe Corporation | Radiation based method locating and differentiating sentinel nodes |
| US5857463A (en) * | 1995-10-13 | 1999-01-12 | Neoprobe Corporation | Remotely controlled apparatus and system for tracking and locating a source of photoemissions |
| US5656815A (en) | 1996-02-08 | 1997-08-12 | The United States Of America As Represented By The Secretary Of The Navy | Thermoluminescence radiation dosimetry using transparent glass containing nanocrystalline phosphor |
| US5811814A (en) | 1996-02-12 | 1998-09-22 | Cordis Corporation | Radiation measuring catheter apparatus and method |
| JP3796635B2 (ja) * | 1996-03-06 | 2006-07-12 | 富士写真フイルム株式会社 | 蛍光検出装置 |
| US5833603A (en) * | 1996-03-13 | 1998-11-10 | Lipomatrix, Inc. | Implantable biosensing transponder |
| US5744805A (en) * | 1996-05-07 | 1998-04-28 | University Of Michigan | Solid state beta-sensitive surgical probe |
| US5932879A (en) | 1996-05-07 | 1999-08-03 | Regents Of The University Of Michigan | Solid state beta-sensitive surgical probe |
| US6076009A (en) * | 1997-05-05 | 2000-06-13 | The University Of Michigan | Solid state beta-sensitive surgical probe |
| DE19621996C2 (de) * | 1996-05-31 | 1998-04-09 | Siemens Ag | Verfahren zur Herstellung einer Kombination eines Drucksensors und eines elektrochemischen Sensors |
| US5682888A (en) | 1996-06-13 | 1997-11-04 | Neoprobe Corporation | Apparatus and system for detecting and locating photon emissions with remote switch control |
| AU721854B2 (en) | 1996-07-11 | 2000-07-13 | Medtronic, Inc. | Minimally invasive implantable device for monitoring physiologic events |
| US5814089A (en) | 1996-12-18 | 1998-09-29 | Medtronic, Inc. | Leadless multisite implantable stimulus and diagnostic system |
| US6862465B2 (en) * | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
| USD424453S (en) | 1997-03-18 | 2000-05-09 | Neoprobe Corporation | Detector unit for radiation detecting probe |
| USD423377S (en) | 1997-03-18 | 2000-04-25 | Neoprobe Corporation | Radiation detecting probe |
| WO1998043700A1 (en) | 1997-03-27 | 1998-10-08 | Alfred E. Mann Foundation For Scientific Research | System of implantable devices for monitoring and/or affecting body parameters |
| AU8031898A (en) | 1997-06-16 | 1999-01-04 | Elan Medical Technologies Limited | Methods of calibrating and testing a sensor for (in vivo) measurement of an analyte and devices for use in such methods |
| CA2215369C (en) * | 1997-09-12 | 2008-11-18 | Nicholas Garry Tarr | Method of monitoring radiation using a floating gate field effect transistor dosimeter, and dosimeter for use therein |
| US5928150A (en) * | 1997-10-04 | 1999-07-27 | Neoprobe Corporation | System for locating and detecting a source of photon emissions |
| US5916167A (en) * | 1997-10-10 | 1999-06-29 | Neoprobe Corporation | Surgical probe apparatus and system |
| US5987350A (en) | 1997-10-10 | 1999-11-16 | Neoprobe Corporation | Surgical probe apparatus and system |
| US6240312B1 (en) * | 1997-10-23 | 2001-05-29 | Robert R. Alfano | Remote-controllable, micro-scale device for use in in vivo medical diagnosis and/or treatment |
| US5891179A (en) * | 1997-11-20 | 1999-04-06 | Paceseter, Inc. | Method and apparatus for monitoring and displaying lead impedance in real-time for an implantable medical device |
| US6239724B1 (en) * | 1997-12-30 | 2001-05-29 | Remon Medical Technologies, Ltd. | System and method for telemetrically providing intrabody spatial position |
| CA2318471A1 (en) | 1998-01-06 | 1999-07-15 | Alexander V. Kirichenko | Nuclear scintigraphic assessment of mucosal function |
| US6087666A (en) * | 1998-02-18 | 2000-07-11 | The United States Of America As Represented By The Secretary Of The Navy | Optically stimulated luminescent fiber optic radiation dosimeter |
| GB9805896D0 (en) | 1998-03-20 | 1998-05-13 | Eglise David | Remote analysis system |
| EP2289423A1 (en) | 1998-05-14 | 2011-03-02 | David N. Krag | System for bracketing tissue |
| AU2001217746A1 (en) | 1998-05-14 | 2002-05-27 | Calypso Medical, Inc. | Systems and methods for locating and defining a target location within a human body |
| US6363940B1 (en) * | 1998-05-14 | 2002-04-02 | Calypso Medical Technologies, Inc. | System and method for bracketing and removing tissue |
| US5939453A (en) | 1998-06-04 | 1999-08-17 | Advanced Polymer Systems, Inc. | PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers |
| US6047214A (en) * | 1998-06-09 | 2000-04-04 | North Carolina State University | System and method for powering, controlling, and communicating with multiple inductively-powered devices |
| US6015390A (en) | 1998-06-12 | 2000-01-18 | D. Krag Llc | System and method for stabilizing and removing tissue |
| US6295680B1 (en) | 1998-07-05 | 2001-10-02 | The Regents Of The University Of Michigan | Method for detecting early atherosclerosis and vascular damage using radioactive tracers and intravascular radiation detection devices |
| US6304766B1 (en) | 1998-08-26 | 2001-10-16 | Sensors For Medicine And Science | Optical-based sensing devices, especially for in-situ sensing in humans |
| CN100385232C (zh) * | 1998-08-26 | 2008-04-30 | 医药及科学传感器公司 | 基于光学的感测装置 |
| ES2316193T3 (es) | 1998-09-30 | 2009-04-01 | Sicel Technologies, Inc. | Procedimientos, sistemas y dispositivos implantables asociados para monitorizacion dinamica de tumores. |
| US6259095B1 (en) * | 1998-10-23 | 2001-07-10 | Neoprobe Corporation | System and apparatus for detecting and locating sources of radiation |
| US6272373B1 (en) | 1998-10-23 | 2001-08-07 | Neoprobe Corporation | Scanning system and method for locating sources of radiation emission |
| US6242741B1 (en) * | 1998-10-23 | 2001-06-05 | United States Surgical Corporation | Radiation detection apparatus |
| US6274159B1 (en) | 1998-10-28 | 2001-08-14 | University Of Florida | Surface modified silicone drug depot |
| US6113795A (en) | 1998-11-17 | 2000-09-05 | The University Of Kansas | Process and apparatus for size selective separation of micro- and nano-particles |
| KR20010102951A (ko) | 1998-12-02 | 2001-11-17 | 추후제출 | 생체내 바이오 센서 장치 및 사용 방법 |
| WO2000040299A1 (en) | 1999-01-06 | 2000-07-13 | Ball Semiconductor, Inc. | Radiation dosimetry system |
| US6179767B1 (en) * | 1999-02-01 | 2001-01-30 | International Business Machines Corporation | Focussing of therapeutic radiation on internal structures of living bodies |
| US6444475B1 (en) | 1999-08-02 | 2002-09-03 | Alltech Associates, Inc. | Ion chromatography apparatus and method for removing gas prior to sample detection |
| US6229684B1 (en) * | 1999-12-15 | 2001-05-08 | Jds Uniphase Inc. | Variable capacitor and associated fabrication method |
| US6614025B2 (en) | 2000-03-28 | 2003-09-02 | Thomson & Nielsen Electronics Ltd. | Radiation sensor and dosimeter incorporating same |
| US7553280B2 (en) * | 2000-06-29 | 2009-06-30 | Sensors For Medicine And Science, Inc. | Implanted sensor processing system and method |
| JP3574383B2 (ja) * | 2000-07-31 | 2004-10-06 | 富士通株式会社 | 半導体装置及びその製造方法 |
| US6717154B2 (en) | 2000-08-02 | 2004-04-06 | Sicel Technologies, Inc. | Evaluation of irradiated foods and other items with telemetric dosimeters and associated methods |
| CA2324048A1 (en) | 2000-10-20 | 2002-04-20 | Wei Ding | Computer assisted radiotherapy dosimeter system and software therefor |
| JP3981328B2 (ja) * | 2000-11-09 | 2007-09-26 | サイセル・テクノロジーズ，インコーポレイテッド | 蛍光タグを使用した生体分子濃縮物をインビボで検出するための方法、回路、および物質の組成物 |
| US6627177B2 (en) * | 2000-12-05 | 2003-09-30 | The Regents Of The University Of California | Polyhydroxyl-substituted organic molecule sensing optical in vivo method utilizing a boronic acid adduct and the device thereof |
| US7011814B2 (en) * | 2001-04-23 | 2006-03-14 | Sicel Technologies, Inc. | Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject |
| US20020193685A1 (en) | 2001-06-08 | 2002-12-19 | Calypso Medical, Inc. | Guided Radiation Therapy System |
| EP1519678A2 (en) * | 2001-10-02 | 2005-04-06 | Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California | Internal biochemical sensing device |
| US20070010726A1 (en) * | 2002-10-02 | 2007-01-11 | Alfred E. Mann Inst. For Biomedical Engineering At The University Of Southern California | Internal biochemical sensing device |
-
2004
- 2004-02-17 WO PCT/US2004/005785 patent/WO2004075032A2/en not_active Ceased
- 2004-02-17 US US10/779,907 patent/US7510699B2/en not_active Expired - Fee Related
- 2004-02-17 EP EP04711947A patent/EP1594551A2/en not_active Withdrawn
- 2004-02-17 AU AU2004214420A patent/AU2004214420A1/en not_active Abandoned
- 2004-02-17 JP JP2006503890A patent/JP4607859B2/ja not_active Expired - Fee Related
- 2004-02-17 CA CA002516497A patent/CA2516497A1/en not_active Abandoned
-
2009
- 2009-02-19 US US12/389,012 patent/US7778695B2/en not_active Expired - Fee Related
-
2010
- 2010-06-25 US US12/823,858 patent/US20100298672A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090180962A1 (en) | 2009-07-16 |
| US7778695B2 (en) | 2010-08-17 |
| AU2004214420A1 (en) | 2004-09-02 |
| US7510699B2 (en) | 2009-03-31 |
| US20100298672A1 (en) | 2010-11-25 |
| EP1594551A2 (en) | 2005-11-16 |
| AU2004214420A2 (en) | 2004-09-02 |
| WO2004075032A3 (en) | 2005-04-14 |
| JP2006520216A (ja) | 2006-09-07 |
| US20040197267A1 (en) | 2004-10-07 |
| WO2004075032A2 (en) | 2004-09-02 |
| JP4607859B2 (ja) | 2011-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7510699B2 (en) | In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes | |
| Lin et al. | Recent advances in autofluorescence-free biosensing and bioimaging based on persistent luminescence nanoparticles | |
| Belykh et al. | Intraoperative fluorescence imaging for personalized brain tumor resection: current state and future directions | |
| AU2002303451B2 (en) | Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject | |
| US6748259B1 (en) | Optical imaging of induced signals in vivo under ambient light conditions | |
| US6081734A (en) | Monitoring system for the regular intake of a medicament | |
| US20060173362A1 (en) | Methods of medical imaging using quantum dots | |
| US20250303001A1 (en) | Systems and methods for super-resolution optical imaging technologies and/or nanosensor-driven patient monitoring and/or treatment | |
| US20180228917A1 (en) | Shielded Targeting Agents, Methods, and In Vivo Diagnostic System | |
| US20110237909A1 (en) | Systems, Circuits and Apparatus For In Vivo Detection of Biomolecule Concentrations Using Fluorescent Tags | |
| AU2002303451A1 (en) | Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject | |
| JP2002543859A (ja) | 光学コントラスト因子を使用して生体内の内部の現場を検出し、位置測定し、及び目標定めする方法及び装置 | |
| Li et al. | Targeted NIR-II emissive nanoprobes for tumor detection in mice and rabbits | |
| Mahmood | Optical molecular imaging approaches in colorectal cancer | |
| Li et al. | Targeted endoscopic imaging | |
| Black et al. | In vivo monitoring of a fluorescently labeled antibody in mice with breast cancer xenografts | |
| Morris | Fluorescent biosensors–promises for personalized medicine | |
| KR20100104370A (ko) | 표피성장인자수용체 다모드 영상용 양자점 기반의 추적자 | |
| Bustamante et al. | In-vivo fluorescence detection of breast cancer growth factor receptors by fiber-optic probe | |
| TW201728352A (zh) | 藥物釋放與檢測裝置、藥物釋放與檢測裝置的操作方法以及偵測螢光物方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20150615 |